Virtual Network's Login.
ESH Gold Institutional Partner
ESH Gold Institutional Partner
ESH Gold Institutional Partner
| Stefan ALIG (Stanford) | Georg LENZ (Muenster) |
| Ash ALIZADEH (Stanford) | Ari MELNICK (New York) |
| Silvia BEA (Barcelona) | David MIKLOS (Stanford) |
| Catherine BOLLARD (Washington) | Teresa PALOMERO (New York) |
| Riccardo DALLA-FAVERA (New York) | Mark ROSCHEWSKI (Bethesda) |
| Alexey DANILOV (Los Angeles) | Gilles SALLES (New York) |
| Silvia DEAGLIO (Turin) | David SCOTT (Vancouver) |
| Moritz FÜRSTENAU (Cologne) | Laurie SEHN (Vancouver) |
| Paolo GHIA (Milan) | Margaret SHIPP (Boston) |
| Michael HALLEK (Cologne) | Louis STAUDT (Bethesda) |
| Daniel HODSON (Cambridge) | Karin TARTE (Rennes) |
| Martin HUTCHINGS (Copenhagen) | Jason WESTIN (Houston) |
| Javeed IQBAL (Omaha) | Wyndham WILSON (Bethesda) |
| Daniel KRAPPMANN (Neuherberg) | Catherine WU (Boston) |
About the Conference:
ESH Translational Research Conferences focus on leading-edge basic, clinical and therapeutic research and future perspectives.
The presentation of unpublished data is encouraged.
This leading-edge translational research conference will address the rapidly evolving field of lymphoid malignancies, including T- and B-cell lymphomas, and chronic lymphocytic leukaemia (CLL), from molecular pathogenesis to state-of-the-art treatment and future perspectives.
The goals of this conference are to:
- foster scientific exchange between laboratory scientists and clinicians working on lymphoid malignancies worldwide.
- foster scientific cross-fertilization between researchers and clinicians working on different diseases with partially overlapping pathogenic mechanisms such as the B cell receptor signaling, alterations of the DNA damage response, or the increasingly important dialogue of lymphoid tumour cells with their microenvironment.
- provide opportunities for leading-edge education and international networking to basic and clinical scientists, including those still in-training
A first-class selection of international speakers will guarantee the highest quality of science and a summary of the most recent developments in the biology and therapy of Lymphoid Malignancies.
CONFERENCE MAIN SCIENTIFIC TOPICS:
- Biology of diffuse large B cell lymphoma subtypes II
- Novel molecular lymphoma subtypes
- Epigenetic and genetic regulation of clonal lymphoma evolution
- Lymphoma cell interactions in the tumor microenvironment
- Monoclonal antibodies & non-cellular immune therapies
- Cellular immune therapies
- Small molecular pathway inhibitors
- Combination therapies
- Use of CT DNA for diagnostic and therapeutic monitoring
LEARNING OBJECTIVES:
- Current developments in the field of molecular pathogenesis of indolent
and aggressive B-cell lymphoma including CLL
- Current developments in the field of the molecular pathogenesis of T-cell lymphoma
- Prognostic and predictive markers and their impact in specific clinical situations
For more information, click here!
With the support of*:
Premium Conference Partner
*******
*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.
